中国医药(600056.SH)：尼麦角林片获得药品注册证书

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. (referred to as "Sanyang Pharmaceutical"), has received the drug registration certificate for Nicergoline Tablets from the National Medical Products Administration, which is expected to enhance the company's product line and strengthen its position in the neurological medication sector [1]. Group 1 - Sanyang Pharmaceutical's Nicergoline Tablets are primarily used to improve motivation deficits caused by sequelae of cerebral infarction and are also applicable for vascular dementia, particularly in early treatment to enhance cognitive and memory functions, as well as to alleviate disease severity [1]. - The approval of the drug registration certificate is beneficial for enriching the company's product portfolio and further developing its presence in the neurological medication field [1]. - This development will accumulate valuable experience for the company's future generic drug development [1].